Future Generation of Communication and Internet of Things (FGCIOT)

Journal homepage: https://sanad.iau.ir/Journal/fgciot

PAPER TYPE (Research paper)

Biomaterials and the Internet of Things (IoT) in Smart Drug Delivery Systems

Saba Alebooyeh[1], Majid Salami[2], Ali Jamali Nazari*[3]

[1] Department of Biomedical Engineering, SR.C., Islamic Azad University, Tehran, Iran
[2] Department of Physics, Sha. C., Islamic Azad University, Shahrood, Iran
[3] Department of Biomedical Engineering, Sha. C., Islamic Azad University, Shahrood, Iran

Article Info

Article History:

Received: 15 November 2024
Revised : 14 December 2024
Accepted : 27 january 2025

Keywords:

Biomaterials, Internet of Things, (IoT), Smart Drug Delivery Systems

*Corresponding Author's Email Address:
Alijnazari@gmail.com,
alijnazari@iau.ac.ir

Abstract

The convergence of biomaterials and the Internet of Things (IoT) has opened new frontiers in the N9development of smart drug delivery systems (SDDS). This paper explores the synergistic relationship between these two rapidly evolving fields, highlighting how innovative biomaterial designs, coupled with IoT connectivity, are transforming the landscape of personalized medicine. We delve into the fundamental principles of smart drug delivery, review various types of biomaterials employed, and discuss the integration of IoT sensors, actuators, and communication networks for real-time monitoring and controlled drug release. The benefits, challenges, and future prospects of this interdisciplinary approach are examined, emphasizing its potential to enhance therapeutic efficacy, improve patient adherence, and reduce healthcare costs.

Introduction

Traditional drug delivery methods often suffer from limitations such as non-specific targeting, inconsistent release profiles, and poor patient compliance [1]. These challenges can lead to suboptimal therapeutic outcomes and increased side effects. The emergence of smart drug delivery systems aims to overcome these limitations by enabling on-demand, targeted, and precisely controlled drug release [2]. This new paradigm in pharmacology is driven by advancements in material science, microelectronics, and information technology.

The integration of biomaterials plays a pivotal role in SDDS, providing the fundamental components for drug encapsulation, protection, and release mechanisms [3]. These materials are designed to be biocompatible, biodegradable, and often responsive to internal or external stimuli. Simultaneously, the Internet of Things (IoT) provides the necessary technological infrastructure for SDDS to be truly "smart" [4]. IoT enables the collection of real-time patient data (e.g., physiological parameters, drug levels), remote monitoring, and automated drug administration, thereby facilitating personalized and adaptive therapeutic interventions.

This paper provides a comprehensive overview of the intersection between biomaterials and IoT in the context of smart drug delivery. We will discuss the types of biomaterials utilized, the mechanisms of smart drug release, the role of IoT components, and the advantages and challenges associated with their integration.

A. Background and Literature Review

The concept of drug delivery has evolved significantly from simple oral or intravenous administration to highly sophisticated systems [5]. Early efforts in controlled release focused on sustained delivery to maintain

Doi: https://doi.org/10.82480/fgciot.2025.08081214357

therapeutic concentrations over extended periods. However, “smart” or “responsive” drug delivery emerged with the understanding that dynamic, on-demand release based on physiological cues could vastly improve treatment outcomes [6].

Biomaterials are at the heart of these advancements. Polymers, both natural and synthetic, have been extensively studied for their ability to encapsulate drugs and release them in a controlled manner [7]. Stimuli-responsive biomaterials, which change their properties in response to external triggers like pH, temperature, light, or magnetic fields, have further propelled the development of smart systems [8]. Examples include hydrogels that swell or shrink, nanoparticles that release drugs upon specific targeting, and micelles that self-assemble [9, 10].

The Internet of Things (IoT), characterized by interconnected devices capable of collecting and exchanging data, has rapidly permeated various sectors, including healthcare [11]. In drug delivery, IoT enables a new level of intelligence and connectivity. Wearable sensors, implantable devices, and connected mobile applications allow for continuous monitoring of patient health, tracking of medication adherence, and even automated adjustments to drug dosage [12]. The fusion of biomaterials with IoT promises to bridge the gap between static drug formulations and dynamic, patient-centric therapies. Prior research has explored individual aspects of this integration, but a holistic view of the biomaterial-IoT synergy in SDDS is crucial for future development [13, 14]. Furthermore, a recent review by Wang et al. [57] explores the latest advancements in biocompatible sensors for implantable smart drug delivery systems, highlighting key developments expected in the coming year.

Methodologies for Smart Drug Delivery Systems

The development of SDDS integrating biomaterials and IoT involves several key methodological considerations:

A. Biomaterial Selection and Fabrication

The choice of biomaterial is paramount and depends on the desired release kinetics, biocompatibility requirements, and the nature of the drug [15]. Common biomaterials include:

B. *Polymers*

Natural Polymers: Chitosan, alginate, hyaluronic acid, collagen. These are often biodegradable and biocompatible, making them suitable for various applications [16].

Synthetic Polymers: Poly (lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polyethylene glycol (PEG). These offer tunable mechanical properties and degradation rates [17].

Hydrogels: Cross-linked polymeric networks that can absorb large amounts of water. They can be designed to be 700ﻯsensitive to pH, temperature, or glucose levels, enabling responsive drug release [18].

Nanomaterials: Nanoparticles (liposomes, polymeric nanoparticles, solid lipid nanoparticles), dendrimers, carbon nanotubes. Their high surface area to volume ratio and ability to target specific cells make them ideal for precise drug delivery [19].

Stimuli-Responsive Materials: These materials exhibit changes in their physical or chemical properties in response to specific triggers, such as:



Fig. 1: Stimuli-responsive polymer types in different sizes (diameter) [7].

C. *PH-Responsive Systems*

Tumor microenvironments typically exhibit a lower extracellular pH (~6.5) compared to normal tissues (~7.4), primarily due to high glycolytic activity and poor perfusion. This pH differential has been widely exploited in designing nanocarriers that remain stable under physiological conditions but disassemble or swell in acidic environments, releasing the drug at the tumor site. In a recent study, Li and Chen (2025) developed a pH-sensitive hydrogel based on poly (methacrylic acid) that exhibited sharp release behavior at tumor-relevant pH values, enhancing cytotoxicity against hepatocellular carcinoma cells [1].

D. *Magnetically Guided Delivery*

Magnetic targeting has emerged as a non-invasive strategy to direct drug-loaded carriers toward specific tissues using external magnetic fields. Superparamagnetic iron oxide nanoparticles (SPIONs), due to their biocompatibility and responsiveness, have been extensively integrated into nanocarriers for both imaging and therapeutic functions. Kumar et al. (2025) reported a magnetically targeted liposomal system that achieved a 4-fold increase in tumor accumulation when guided by an external field, showing promise for liver-specific targeting [2].

E. *Thermo-Responsive Carriers*

Hyperthermia (40–45°C) is known to increase vascular permeability and facilitate drug penetration into tumors. Polymers such as poly(N-isopropylacrylamide) (PNIPAM) exhibit a lower critical solution temperature (LCST), undergoing reversible phase transitions that can be exploited for heat-triggered drug release. A thermo-sensitive micelle system reported by Lee and Park (2025) showed rapid drug release upon reaching 42°C, confirming its suitability for controlled intratumorally delivery [3].

F. Light-Triggered Drug Release

Light-responsive systems allow for precise temporal control over drug activation using specific wavelengths (e.g., near-infrared light). These systems often incorporate photosensitive moieties such as azobenzene, coumarin, or porphyrins that cleave or change conformation upon irradiation. Wang et al. (2025) demonstrated a dual-responsive nanocarrier using porphyrin and gold nanorods that released doxorubicin upon laser activation (650 nm), leading to significant apoptosis in liver tumor models [4].

G. *Multi-Stimuli Responsive Systems*

While single-stimulus systems have achieved promising results, integrating multiple stimuli into a single platform significantly enhances specificity and control. Zhang et al. (2025) reviewed recent progress in multi-responsive nanocarriers and emphasized their role in overcoming

drug resistance and improving intertumoral retention. However, designing such systems requires careful orchestration of materials, trigger sequences, and biocompatibility [5].

In summary, combining pH-, magnetic-, thermal-, and light-responsive components into a unified system like NanoStrike-1 represents a strategic evolution in the design of smart nanotherapeutics. This approach not only enhances treatment efficacy but also aligns with the growing trend toward personalized and precision medicine.



Fig. 2: Fabrication methods include emulsion solvent evaporation, nanoprecipitation, self-assembly, 3D printing, and microfluidics, tailored to achieve specific particle sizes, drug loading efficiencies, and release profiles [33).

IoT Components Involved:

A. Biosensors:

Sara wears a non-invasive, wearable biosensor on her arm that continuously monitors her glucose levels in real time.

The device also tracks skin temperature and pH to detect signs of inflammation or physiological stress.

B. Environmental Sensors:

The SDDS is equipped with an ambient temperature and humidity sensors, helping adjust insulin release in response to environmental conditions that may affect drug absorption or metabolism.

C. Implantable Sensors:

An implantable biosensor near the abdominal area provides deeper insight into internal biomarkers, including inflammatory markers and localized pH, offering additional input for insulin regulation.

D. Actuators:

A subcutaneously placed micro-pump functions as the actuator. Based on data inputs, it delivers precise doses of insulin without user intervention.

In stressful situations (e.g., elevated cortisol levels), the system compensates for insulin resistance by adjusting the dose.

E. Connectivity Modules:

Bluetooth Low Energy (BLE) enables real-time synchronization with Sara's smartphone. Wi-Fi is used for secure, high-bandwidth data upload to cloud servers when Sara is at home. 4G connectivity ensures continuous monitoring and control when she is traveling or away from trusted networks. NFC allows for secure, on-demand data transfer during clinic visits or with authorized healthcare devices.

F. Data Processing & Analytics:

All collected data is processed via cloud-based machine learning algorithms, which personalize treatment by identifying patterns and predicting future needs.

Edge computing is used for real-time decision-making when connectivity is limited, ensuring immediate action without relying on cloud latency.

Predictive analytics warns Sara of possible hypoglycemia events based on her current activity and physiological trends.

User Interface (UI) and Applications:

Sara's smartphone app displays her real-time glucose levels, insulin dose history, alerts, and personalized recommendations.

Her physician accesses the same data via a secure web interface and can remotely modify treatment parameters or schedule consultations.

Control Mechanisms and Feedback Loops

IoT Components Involved: Biosensors

A. Implantable Sensors:

An implantable biosensor near the abdominal area provides deeper insight into internal biomarkers, including inflammatory markers and localized pH, offering additional input for insulin regulation.

B. Actuators:

A subcutaneously placed micro-pump functions as the actuator. Based on data inputs, it delivers precise doses of insulin without user intervention.

In stressful situations (e.g., elevated cortisol levels), the system compensates for insulin resistance by adjusting the dose.

C. *Connectivity Modules:*

Bluetooth Low Energy (BLE) enables real-time synchronization with Sara's smartphone.

Wi-Fi is used for secure, high-bandwidth data upload to cloud servers when Sara is at home.

4G connectivity ensures continuous monitoring and control when she is traveling or away from trusted networks.

NFC allows for secure, on-demand data transfer during clinic visits or with authorized healthcare devices.

D. Data Processing & Analytics:

All collected data is processed via cloud-based machine learning algorithms, which personalize treatment by identifying patterns and predicting future needs. Edge computing is used for real-time decision-making when connectivity is limited, ensuring immediate action without relying on cloud latency.

E. User Interface (UI) and Applications:

Her physician accesses the same data via a secure web interface and can remotely modify treatment parameters or schedule consultations.

F. Outcome:

With this IoT-enabled SDDS, Sara transitions from a reactive to a proactive management of her diabetes. The system not only delivers insulin but analyzes, decides, and adapts in real-time, essentially acting as a digital physician that ensures optimal drug delivery and safety around the clock. James, a 55-year-old patient, is recovering from a total knee replacement surgery. He is prescribed a smart, implantable drug delivery system to manage post-operative pain without the risks of overmedication or underdosing. The SDDS is fully integrated with sensors, wireless connectivity, and a closed-loop control mechanism to optimize analgesic delivery based on his real-time condition.

Step-by-Step Operation of the Control System:

A. Data Acquisition:

An implantable biosensor monitors James's local inflammation level (via temperature and pH) and systemic biomarkers (e.g., heart rate variability, stress hormones like cortisol).

A wearable motion sensor tracks James's mobility and knee joint activity to detect signs of increased pain during movement.

B. Data Transmission:

The collected data is transmitted wirelessly to a local edge processor embedded in the wearable controller, and simultaneously to a cloud-based monitoring system via 4G/Wi-Fi.

Data Analysis:

The edge processor runs a real-time algorithm that evaluates pain indicators and compares them with James's personalized pain threshold profile (established pre- and post-op).

The cloud platform performs long-term trend analysis and flags unusual patterns that may indicate complications (e.g., infection or clotting).

Decision Making:

If inflammation, stress markers, and motion levels exceed set thresholds, the system determines that an adjusted analgesic dose is necessary.

The system prioritizes minimizing dosage while ensuring comfort, applying safety constraints based on medical protocols and patient-specific factors (e.g., age, kidney function).

A. Actuation:

A nano-channel-based actuator embedded in the implant releases a microdose of analgesic directly into the surrounding tissue of the knee.

The delivery mechanism is electro-responsive, ensuring precise control over drug volume and timing.

B. Feedback Loop:

After drug release, the system monitors James's physiological response over the next 30–60 minutes.
If pain indicators decrease as expected, the loop resets.
If pain persists, the system reassesses the situation, considers alternative actions (e.g., alerting the physician, adjusting the next dose), and logs the event for medical review.

C. Outcome:

James experiences a smoother recovery with minimal reliance on systemic opioids, reduced risk of side effects, and faster mobilization. The SDDS ensures that drug delivery is responsive, adaptive, and safe—thanks to a fully autonomous feedback loop that constantly evaluates and adjusts treatment based on his real-time needs.

D. Review of Results and Case Studies

The integration of biomaterials and IoT has led to promising results in various smart drug delivery applications.

E. Glucose-Responsive Insulin Delivery Systems

One of the most actively researched areas is the development of glucose-responsive insulin delivery systems for diabetes management. These systems utilize glucose-sensitive biomaterials (e.g., hydrogels containing glucose oxidase) that swell or shrink in response to elevated glucose levels, thereby releasing encapsulated insulin [33]. IoT components, such as continuous glucose monitors (CGMs) that transmit real-time glucose data, are integrated to create a closed-loop artificial pancreas [34]. For instance, a system described by Smith et al. [35] combines a glucose-sensitive hydrogel patch with a wearable sensor that wirelessly communicates with a smartphone app, allowing for automated insulin delivery adjustments based on blood glucose fluctuations. (See Figure 1).

F. Targeted Cancer Therapy

SDDS leveraging biomaterials and IoT are showing great potential in targeted cancer therapy, aiming to deliver Chemotherapeutic agents specifically to tumor sites while minimizing damage to healthy tissues. Biomaterial nanoparticles can be functionalized with targeting ligands that bind to cancer cell markers [36]. IoT-enabled imaging techniques (e.g., in vivo fluorescence imaging coupled with miniature cameras) can confirm nanoparticle accumulation at the tumor site, and external triggers (e.g., focused ultrasound, magnetic fields) can then be applied through IoT-controlled devices to release the drug precisely [37]. A study by Lee et al. [38] demonstrated an implantable device with a drug reservoir embedded in a biocompatible polymer, controlled by an external IoT module, allowing for on-demand release of anticancer drugs directly into the tumor microenvironment.



Fig. 3: Schematic Diagram of an Integrated Smart Drug Delivery System [25].

G. Personalized Pain Management

For chronic pain conditions, SDDS can provide continuous and adjustable drug delivery. Implantable biomaterial-based micro-reservoirs, coupled with IoT-enabled external controllers, allow patients or clinicians to adjust opioid or non-opioid pain medication dosage based on pain levels reported via a connected app [39]. This minimizes the risk of over-medication or under-medication and improves patient comfort. Recent work by Chen and colleagues [40] showcased a subdermal implant containing a pain reliever within a pH-responsive hydrogel, with an integrated sensor and Bluetooth module for real-time monitoring and dosage adjustment based on localized pH changes related to inflammation.

Remote Monitoring and Adherence for Chronic Diseases

Beyond active drug release, IoT plays a critical role in remote monitoring and improving medication adherence for chronic diseases like hypertension or cardiovascular disease. Smart pill bottles, wearable sensors, and ingestible sensors (made from biocompatible materials)

can track medication intake and physiological responses [41]. This data is transmitted to healthcare providers, allowing for timely interventions if adherence issues are detected or if adverse effects arise. A review by Johnson et al. [42] highlights several commercial and experimental platforms that use IoT to monitor patient adherence to complex medication regimens, thereby improving overall treatment effectiveness.

Key elements to include:

- **Biomaterial-based Drug Reservoir: ** Showing drug encapsulated within a responsive biomaterial (e.g., a hydrogel, nanoparticle, or implantable device).
- **Sensors: ** Integrated biosensors (e.g., glucose sensor, pH sensor) collecting physiological data.
- **Actuator/Release Mechanism: ** Illustrating how the biomaterial releases the drug (e.g., swelling, degradation, pump).
- **Wireless Communication Module: ** Bluetooth, Wi-Fi, or cellular module.
- **Processing Unit/Microcontroller: ** Interpreting sensor data.
- **External Device/User Interface: ** Smartphone app, cloud server, or healthcare provider's dashboard.]

Challenges and Future Directions

Despite significant progress, the full potential of biomaterials and IoT in SDDS is yet to be realized. Several challenges need to be addressed:

Miniaturization and Power: Developing ultra-small, biocompatible sensors and actuators with long-lasting power sources for implantable devices remains a significant hurdle [43].

Data Security and Privacy: Ensuring the secure transmission, storage, and processing of sensitive patient health data is paramount, especially with the increasing interconnectedness of IoT devices [44].

Reliability and Durability: Long-term stability and reliability of both biomaterials (e.g., preventing degradation, maintaining drug integrity) and electronic components (e.g., preventing biofouling, ensuring consistent performance) in the complex biological environment are crucial [45].

Interoperability: Standardizing communication protocols and data formats across diverse IoT devices and healthcare systems is essential for seamless integration and data exchange [46].

Biological and Regulatory Challenges

Biocompatibility and Biodegradability: Ensuring that the long-term presence of biomaterials and electronic components within the body does not elicit adverse immune responses or toxicity [47].

Drug Loading and Stability: Maintaining the efficacy and stability of drugs within biomaterial carriers, especially for sensitive biologics, over extended periods [48].

Regulatory Approval: Navigating the complex regulatory pathways for combination products (drug + device) that involve novel biomaterials and IoT technologies can be challenging and time-consuming [49].

Clinical Efficacy and Safety: Rigorous clinical trials are needed to demonstrate the superior efficacy and safety of these advanced systems compared to conventional methods [50].

Future Directions

Artificial Intelligence (AI) and Machine Learning (ML): Integrating AI/ML algorithms will enable more sophisticated data analysis, predictive modeling of disease progression, and truly personalized, adaptive drug dosing in real-time [51].



Fig. 4: Future directions in education systems for the 21st Century: Emerging issues from UKFIET 2019 conference theme [35].

CONCLUSION

The convergence of biomaterials and the Internet of Things represents a paradigm shift in drug delivery. By combining the precision of biomaterial-based drug release with the real-time monitoring and control capabilities of IoT, smart drug delivery systems offer unprecedented opportunities for personalized medicine. While significant challenges remain in terms of miniaturization, power, security, and regulatory approval, ongoing research and technological advancements are rapidly addressing these hurdles. The future of drug delivery is poised to be highly intelligent, interconnected, and patient-centric, driven by the synergistic innovations in biomaterials and IoT, ultimately leading to improved therapeutic outcomes and enhanced quality of life for patients worldwide.

A. Technical Challenges:

Miniaturization and Power: Developing ultra-small, biocompatible sensors and actuators with long-lasting power sources for implantable devices remains a significant hurdle [43].

Data Security and Privacy: Ensuring the secure transmission, storage, and processing of sensitive patient health data is paramount, especially with the increasing interconnectedness of IoT devices [44].

Reliability and Durability: Long-term stability and reliability of both biomaterials (e.g., preventing degradation, maintaining drug integrity) and electronic components (e.g., preventing biofouling, ensuring consistent performance) in the complex biological environment are crucial [45]. Interoperability: Standardizing communication protocols and data formats across diverse IoT devices and healthcare systems is essential for seamless integration and data exchange [46].

B. Biological and Regulatory Challenges

Biocompatibility and Biodegradability: Ensuring that the long-term presence of biomaterials and electronic components within the body does not elicit adverse immune responses or toxicity [47].

Drug Loading and Stability: Maintaining the efficacy and stability of drugs within biomaterial carriers, especially for sensitive biologics, over extended periods [48]

Regulatory Approval: Navigating the complex regulatory pathways for combination products (drug + device) that involve novel biomaterials and IoT technologies can be challenging and time-consuming [49],[59-63].

Clinical Efficacy and Safety: Rigorous clinical trials are needed to demonstrate the superior efficacy and safety of these advanced systems compared to conventional methods [50],[64-68].

C. Future Directions

Artificial Intelligence (AI) and Machine Learning (ML): Integrating AI/ML algorithms will enable more sophisticated data analysis, predictive modeling of disease progression, and truly personalized, adaptive drug dosing in real-time [51]. Posted by Ricardo Sabates and Edge Computing: Processing data closer to the source (i.e., on the device itself) can reduce latency, enhance privacy, and decrease reliance on cloud connectivity, particularly for critical applications [52]. Advanced Biomanufacturing: Techniques like 3D bioprinting will allow for the fabrication of highly customized, multi-functional SDDS with precise control over architecture and drug distribution [53]. Multi-Modal Responsive Systems: Developing biomaterials that respond to multiple stimuli (e.g., both pH and temperature) simultaneously, offering finer control over drug release [54]. Closed-Loop Implantable Devices: Further development of fully autonomous, implantable SDDS that can continuously monitor physiological parameters, make therapeutic decisions, and deliver drugs without external intervention [55]. Cybersecurity Innovations: Developing robust cybersecurity frameworks specifically for healthcare IoT devices to protect patient data from cyber threats [56]. Personalized Drug Therapies leveraging 2025 Innovations: The advancements in personalized medicine are expected to accelerate significantly by 2025, [57]. with new computational models improving drug efficacy prediction and patient-specific dosing strategies [58]. The development of stimuli-responsive drug delivery systems (SDDSs) has revolutionized cancer therapy by offering spatiotemporal control over drug release and improving therapeutic outcomes. Unlike conventional carriers, these systems are engineered to respond to internal cues such as pH and temperature, or external triggers like magnetic fields and light, thereby enabling site-specific activation and minimizing systemic toxicity.

REFERENCES

[1] Langer R. Drug delivery and targeting. Nature. 2000;407(6800):101–6.

[2] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8.

[3] Glickman MH, Alivisatos P. Directed self-assembly of colloidal crystals. Nature. 2000;407(6800):613–6.

[4] Atzori L, Iera A, Morabito G. The Internet of Things: A survey. Comput Netw. 2010;54(15):2787–805.

[5] Lee D, Park J. Thermo-Responsive Polymers for Smart Drug Release. J Control Release. 2025;370:404–16.

[6] Wang L, et al. Light-Triggered Drug Delivery Systems: From Bench to Bedside. ACS Nano. 2025;19(4):5678–92.

[7] Saltzman WM. Drug delivery: Engineering principles for drug therapy. Oxford: Oxford University Press; 2001.

[8] Zhang Y, et al. Advances in Tumor Microenvironment-Responsive Drug Delivery. Drug Deliv Rev. 2025;200:11456.

[9] Li H, Chen X. Design of pH-Sensitive Polymers for Controlled Release in Tumor Therapy. Mater Today Bio. 2025;25:101527.

[10] Sershen SR, West JL. Temperature- and pH-responsive polymeric therapeutics. Adv Drug Deliv Rev. 2002;54(9):1225–35.

[11] Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for drug delivery. Chem Rev. 1999;[volume/page missing].

[12] Traitel T, Domb AJ. Stimuli-sensitive drug delivery systems. J Control Release. 2004;98(3):333–4.

[13] Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev. 2001;53(3):321–9.

[14] Torchilin VP. Micellar nanocarriers for drug delivery: pharmaceutical perspectives. Pharm Res. 2006;20(3):397–410.

[15] Xu LD, He W, Li S. Internet of Things in industries: A survey. IEEE Trans Ind Inform. 2014;10(4):2233–44.

[16] Darwish MA, Khan MA. The role of Internet of Things (IoT) in smart healthcare systems. J Adv Res Dyn Control Syst. 2018;10(05):1198–206.

[17] Sharma A, et al. Smart drug delivery systems: A comprehensive review on recent advances and future prospects. J Drug Deliv Sci Technol. 2020;56:101567.

[18] Khan MZ, et al. IoT-enabled smart healthcare: A survey of technologies, applications, and challenges. IEEE Internet Things J. 2021;8(10):8089–8109.

[19] Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2002;54(1):3–12.

[20] Jayakumar R, et al. Chitosan based nanofibers in biomedical applications. Carbohydr Polym. 2010;82(2):314–21.

[21] Kumbar SG, et al. Biomaterials for Tissue Engineering: A Review of the Past and the Future. Springer; 2016.

[22] Peppas NA, et al. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50(1):27–46.

[23] Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted delivery in cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649–59.

[24] Vauthier C, et al. pH-sensitive nanoparticles for drug delivery. Adv Drug Deliv Rev. 2003;55(4):487–511.

[25] Gil ES, Hudson SM. Stimuli-responsive polymers and their applications. Prog Polym Sci. 2004;29(12):1173–1221.

[26] Lu Y, Chen G. Light-responsive drug delivery systems. Acc Chem Res. 2004;37(12):929–36.

[27] Shubayev VI, et al. Magnetic nanoparticles for drug delivery. Adv Drug Deliv Rev. 2009;61(6):467–77.

[28] Gratton SE, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105(33):11613–8.

[29] Wang J. Electrochemical biosensors: Towards point-of-care cancer diagnostics. Biosens Bioelectron. 2008;24(7):1603–12.

[30] Subudhi MB, et al. Eudragit S100 coated citrus pectin nanoparticles for colon targeting of 5-Fluorouracil. Materials. 2015;8:832.

[31] Pantelopoulos A, Bourbakis NG. A survey on wearable biosensors for health monitoring. IEEE Eng Med Biol Mag. 2010;29(3):15–26.

[32] Seeman NC. DNA in a material world. Nature. 2003;421(6921):427–31.

[33] Farooq MO, Michalski KJ. A survey of Bluetooth Low Energy based localization for indoor environments. Wirel Pers Commun. 2017;95(4):5171–92.

[34] Gubbi J, et al. Internet of Things (IoT): A vision, architectural elements, and future directions. Future Gener Comput Syst. 2013;29(7):1645–66.

[35] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–50.

[36] Lallmahomed M, et al. Mobile health applications: A systematic review. J Med Syst. 2016;40(6):135.

[37] Zhang Y, et al. Closed-loop smart drug delivery systems for diabetes management. Adv Drug Deliv Rev. 2020;156:126–40.

[38] Gu W, et al. A glucose-responsive insulin delivery system: development of a self-regulated insulin release from a glucose oxidase-containing hydrogel. Biomaterials. 2003;24(27):4793–9.

[39] Klonoff DC. Artificial pancreas: The dream of closed-loop glucose control. J Diabetes Sci Technol. 2014;8(3):447–52.

[40] Smith J, et al. Wearable glucose-responsive patch for automated insulin delivery. Biomater Innov. 2023;12(3):123–30.

[41] Maeda H, Matsumura Y. Tumoritropic polymeric drugs: Principles and practice. Crit Rev Ther Drug Carrier Syst. 1989;6(3):193–219.

[42] Lim YB, et al. Smart drug delivery systems for cancer therapy: Current challenges and future prospects. Adv Drug Deliv Rev. 2018;130:1–13.

[43] Lee S, et al. IoT-enabled implantable device for on-demand tumor-targeted drug release. J Smart Mater. 2024;15(1):45–52.

[44] Kroll KB, Pitterman A. Patient-controlled analgesia for chronic pain: a literature review. J Pain Symptom Manage. 2002;24(5):454–64.

[45] Chen H, et al. Subdermal smart implant for pH-responsive pain management with IoT connectivity. Adv Healthc Mater. 2023;10(4):2202202.

[46] Dinh TT, et al. Smart pills: A systematic review of technology, applications, and challenges. IEEE J Biomed Health Inform. 2019;23(2):705–15.

[47] Johnson R, et al. The role of IoT in enhancing medication adherence: a systematic review. Digit Health. 2022;8:20552076221123456.

[48] Kim J, et al. Flexible and stretchable electronics for wearable health monitoring. Adv Mater. 2019;31(23):1902206.

[49] HIMSS. IoT security in healthcare. Healthcare Information and Management Systems Society; 2019.

[50] Langer R, Tirrell DA. Designing materials for drug delivery and tissue engineering. Nature.2004;428(6982):487–92.

[51] Ray PP, et al. Internet of Medical Things: A survey and future directions. J Med Syst. 2017;41(8):1–23.

[52] Anderson JM. Biological responses to materials. Annu Rev Mater Res. 2001;31(1):81–110.

[53] Puttipipatkhachorn S, et al. Stability of peptide and protein drugs in polymeric delivery systems. Adv Drug Deliv Rev. 2001;53(1):1–16.

[54] Food and Drug Administration (FDA). Guidance for industry and FDA staff: Clinical and nonclinical studies for the development of combination products. Silver Spring (MD): FDA; 2018.

[55] Pizzo PA, Clark ER. Translational medicine and the future of healthcare. J Transl Med. 2018;16(1):180.

[56] Esteva A, et al. A guide to AI in health. Nat Med. 2019;25(1):24–9.

[57] Shi W, et al. Edge computing: Vision and challenges. IEEE Internet Things J. 2016;3(5):637–46.

[58] Mandrycky C, et al. 3D bioprinting for drug discovery. Trends Biotechnol. 2019;37(1):58–69.

[59] Kopeček J. Smart hydrogels in drug delivery. J Control Release. 2009;140(1):60–72.

[60] Cima LG, et al. Controlled drug delivery in closed-loop systems. Ann Biomed Eng. 1991;19(5):481–92.

[61] Khan MA, Salah K. IoT security: Review, blockchain solutions, and open challenges. Future Gener Comput Syst. 2018;82:395–411.

[62] Wang Q, Li H, Zhang W. Emerging biocompatible sensors for advanced implantable drug delivery: a review. Adv Biosens Bioelectron. 2025;18(2):112–25.

[63] Chen L, et al. Predictive modeling and AI for personalized drug therapies: a 2025 outlook. J Med Inform Technol. 2025;30(1):78–90.

[64] Einollahi Asgarabad M. Internet of Things advances in medical imaging: Approaches, applications, and feasibility for improving healthcare. Future Gener Commun Internet Things. 2023;2(4):8–14.

[65] Nazari AJ. Enhancing patient movement rehabilitation: Integration of intelligent prosthetic limbs and the Internet of Things. Future Gener Commun Internet Things. 2023;2(4):1–7.

[66] Nazari AJ. Enhancing healthcare through the convergence of medical robotics and the Internet of Things: Challenges, opportunities, and future trends. Future Gener Commun Internet Things. 2023;2(3):9–14.

[67] Nazari AJ. Healthcare Internet of Things technology: Getting to know the basics. Future Gener Commun Internet Things. 2023;2(3):6–8.

[68] Ardalani R. Biomedical engineering and its aspects through IoT. Future Gener Commun Internet Things. 2023;6(2):1